Inactive Instrument

News Synageva Biopharma Corp

Equities

US87159A1034

End-of-day quote Nasdaq Other stock markets
- ^USD	-

2015

Alexion Pharmaceuticals : to bolster rare disease offering with $8.4 billion deal

Summary

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Synageva Biopharma : Alexion Completes Acquisition of Synageva	15-06-23	BU
Synageva BioPharma : Completes Targeted Enrollment in Phase 1/2 Trial with SBC-103 for Mucopolysaccharidosis IIIB	15-06-04	PR
Synageva BioPharma : Submits Kanuma(TM) (Sebelipase Alfa) Application For LAL Deficiency In Japan	15-05-26	PR
Alexion Pharmaceuticals : to bolster rare disease offering with $8.4 billion deal	15-05-06	RE
Synageva BioPharma : Reports First Quarter 2015 Financial Results and Provides General Business Updates	15-04-29	PR
Synageva BioPharma : Submits Kanuma(TM) (Sebelipase Alfa) Application For LAL Deficiency In Mexico	15-03-30	PR
Synageva BioPharma : Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015	15-02-27	PR
Synageva BioPharma : Reports 2014 Full Year Financial Results	15-02-26	PR
Synageva BioPharma : To Present At The Cowen and Company Health Care Conference	15-02-25	PR
Synageva Biopharma : FDA Accepts BLA Filing For Synageva's Kanuma(TM) (Sebelipase Alfa); Grants Priority Review And Assigns PDUFA Date	15-02-23	PR
Synageva BioPharma : To Host 2014 Fourth Quarter And Full Year Financial Results Conference Call On February 26	15-02-19	PR
Synageva Biopharma : A Look at the Latest Occurrences in the Healthcare Sector: Special Research on Sangamo BioSciences,Seattle Genetics, StemCells, Synageva and VBI Vaccines	15-02-19	PR
Synageva Biopharma : European Patent Issued For Treatment Of LAL Deficiency	15-02-18	PR
Synageva BioPharma : Announces Presentations At 11th Annual World Symposium	15-02-11	PR
Synageva BioPharma : Announces Dosing Of Patients Commenced With SBC-103 In Phase 1/2 Study For Mucopolysaccharidosis IIIB And FDA Fast Track Designation Granted	15-01-26	PR
Synageva BioPharma : Announces Pricing of Public Offering of Common Stock	15-01-06	PR
Synageva BioPharma : Announces A 2.5 Million Share Proposed Public Offering Of Its Common Stock	15-01-05	PR
Synageva BioPharma : Announces New Pipeline Programs And Other Company Progress	15-01-05	PR
Synageva BioPharma : Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA	14-12-23	PR
Synageva BioPharma : To Present At The 33rd Annual J.P. Morgan Healthcare Conference On Monday, January 12, 2015 at 9:00 a.m. PST	14-12-17	PR

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Synageva Biopharma Corp

Equities

US87159A1034

Summary

Filters